HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NVS
Novartis AG
NVS's fundamentals are mixed, but it looks expensive: trading at 31x earnings, above its usual 19x. Its downside scenario is about four times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
NVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $67.63 | -58% |
| Fair | 19x | $98.78 | -38% |
| Expensive | 26x | $134 | -16% |
| Current | 31x | $160 | — |
Historical ranges are pointers, not guarantees.
NVS's PE is in its expensive range at 31x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NVS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
NVS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $5.24 | -28% |
| Q2 2026 | $6.63 | -3.4% |
| Q1 2026 | $6.98 | +9.2% |
| Q4 2025 | $7.15 | +22% |
| Q3 2025 | $7.31 | -15% |
| Q2 2025 | $6.86 | -13% |
| Q1 2025 | $6.39 | -13% |
| Q4 2024 | $5.88 | -18% |
NVS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15B | +4.7% |
| Q2 2026 | $14.4B | -2.8% |
| Q1 2026 | $13.5B | -0.7% |
| Q4 2025 | $13.3B | -1.6% |
| Q3 2025 | $14.4B | +9% |
| Q2 2025 | $14.8B | +15% |
| Q1 2025 | $13.6B | +12% |
| Q4 2024 | $13.6B | +15% |
NVS's revenue has held roughly level: $15B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -19 points |
| Q2 2026 | 33% | +0.1 points |
| Q1 2026 | 31% | -2.9 points |
| Q4 2025 | 26% | +0.4 points |
| Q3 2025 | 31% | +3.8 points |
| Q2 2025 | 33% | +1.6 points |
| Q1 2025 | 34% | +6.4 points |
| Q4 2024 | 26% | +4.1 points |
NVS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NVS on cash flow, with more consistent year-over-year improvement.
NVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | -17% |
| Q2 2026 | $5.6B | -8.8% |
| Q1 2026 | $2.9B | +33% |
| Q4 2025 | $1.6B | -46% |
| Q3 2025 | $5.7B | +4.6% |
| Q2 2025 | $6.1B | +47% |
| Q1 2025 | $2.2B | +94% |
| Q4 2024 | $3.1B | +43% |
NVS's free cash flow has been positive every quarter for seven years: $14.8B over the past year, down 13% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -9M shares |
| 1 year | -1.8% | -35M shares |
| 3 years | -8.2% | -170M shares |
| 5 years | -15% | -349M shares |
| Available history | -17% | -387M shares |
NVS has 1.9B diluted shares, down 1.8% from a year ago, with $6.2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.7B |
| Q2 2026 | $1.2B |
| Q1 2026 | $1.9B |
| Q4 2025 | $1.5B |
| Q3 2025 | $2.3B |
| Q2 2025 | $2.7B |
| Q1 2025 | $2.7B |
| Q4 2024 | $2.8B |
NVS spent $6.2B buying back its own shares over the past year, down 40% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.8x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
NVS's net debt is about 1.8 years of its operating earnings (EBITDA), up from a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.3 | Neutral |
| Stochastic | 85.0 | Overbought |
NVS's weekly RSI is 57 (neutral) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NVS PE vs Healthcare Sector
| Metric | NVS | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 18% above |
| PE % | 98 | 29 | 69 pts above |
NVS is trading at 31x earnings, a 18% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $151.9 | 5.5% above |
| 20 week MA | $152.6 | 5% above |
| 50 week MA | $150.5 | 6.5% above |
| 100 week MA | $133.2 | 20% above |
| 200 week MA | $116.3 | 38% above |
NVS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $90.3 | $83.8 | -7.2% |
| 2021 | $83.8 | $82.0 | -2.1% |
| 2022 | $82.0 | $86.0 | +4.9% |
| 2023 | $86.0 | $101.0 | +17% |
| 2024 | $101.0 | $98.4 | -2.6% |
| 2025 | $98.4 | $139.2 | +41% |
| 2026 YTD | $139.2 | $160.3 | +15% |
NVS has the edge over HIMS on returns for 2026, with the stronger performance.